Neocafen20 mg/ml

Neocafen is an FDA-approved methylxanthine stimulant indicated for the short-term treatment of apnea of prematurity in premature infants (approximately 28 to less than 33 weeks gestational age). It is administered only in a hospital setting, typically a neonatal intensive care unit (NICU), under the supervision of a neonatologist or pediatric specialist.

• Established/FDA-approved use: Treatment of apnea of prematurity to reduce the frequency of apnea episodes and reduce the need for mechanical ventilation.
• Guideline-supported use: Reduction of bronchopulmonary dysplasia risk and facilitation of extubation in preterm infants, as supported by neonatal clinical literature.

Neocafen is not indicated for use in full-term infants, older children, or adults.

Each mL of Caffeine Citrate injectable/oral solution typically contains caffeine citrate equivalent to 20 mg caffeine citrate (10 mg caffeine base) per mL. Strength and concentration may vary by manufacturer/brand; refer to the specific product label for exact composition.

Neocafen is a citrate salt of caffeine, a methylxanthine derivative, formulated as a sterile, preservative-free, ready-to-use solution for intravenous or oral administration in premature infants. It acts as a central nervous system and respiratory stimulant used specifically in the neonatal intensive care setting.

Neocafen belongs to the methylxanthine class of drugs, which also includes theophylline and theobromine. Within this class it is classified as a central nervous system and respiratory stimulant used in neonatology.

Caffeine Citrate works primarily by non-selectively antagonizing adenosine receptors (A1 and A2A) in the central nervous system, which increases respiratory drive and minute ventilation, improves diaphragmatic contractility, and increases sensitivity of the respiratory center to carbon dioxide. Additional proposed mechanisms include mild phosphodiesterase inhibition, contributing to reduced frequency of apneic episodes in premature infants.

Following administration, Caffeine Citrate is well absorbed, with a volume of distribution of approximately 0.8-0.9 L/kg in neonates, and undergoes hepatic metabolism via CYP1A2 (an immature pathway in neonates), with a markedly prolonged elimination half-life of approximately 3-4 days in preterm infants (compared to about 5 hours in adults), due to hepatic and renal immaturity.

Neocafen loading doses are given by slow intravenous infusion over 30 minutes using an infusion pump. Maintenance doses may be given intravenously over 10 minutes or orally (via nasogastric/orogastric tube or by mouth) once daily. Neocafen is supplied as a preservative-free, ready-to-use solution; any unused portion should be discarded. It must only be administered by trained healthcare professionals in a monitored hospital setting.

Neocafen should not be used concurrently with theophylline, as both are methylxanthines that interconvert in preterm neonates, increasing the risk of additive toxicity (tachycardia, jitteriness, seizures).

Neocafen is metabolized via hepatic CYP1A2; concurrent use with CYP1A2 inhibitors (e.g., cimetidine, certain macrolide antibiotics) may reduce clearance and increase caffeine levels, while CYP1A2 inducers may reduce efficacy. Caution is advised with other CNS stimulants due to additive stimulant effects, and with drugs affecting cardiac rhythm given the chronotropic effects of Neocafen.

Adverse effects associated with Neocafen include:

• Common: Tachycardia, jitteriness, restlessness, feeding intolerance, and mild gastrointestinal upset.
• Less common but clinically important: Necrotizing enterocolitis-like symptoms, gastritis, hyperglycemia, and rash.
• Rare/serious: Seizures (typically associated with overdose or very high serum levels).

Neocafen is a medication administered to premature infants after birth and is not intended for use during pregnancy. It carries a historical FDA Pregnancy Category C classification; animal studies at high doses have shown teratogenic effects (cleft palate, skeletal abnormalities). If a breastfeeding mother is taking caffeine-containing products, small amounts of caffeine may pass into breast milk; a physician should be consulted regarding any monitoring needed for the infant. Neocafen should be used only under direct medical supervision, with potential benefit clearly justifying potential risk per physician guidance.

Neocafen requires close monitoring for necrotizing enterocolitis, particularly in very preterm infants; monitoring for this complication should continue as part of routine neonatal intensive care regardless of caffeine therapy. Because it can increase heart rate and cardiac output, Neocafen should be used cautiously in infants with underlying cardiovascular conditions. Use with caution in infants with a history of seizure disorder, and monitor for signs of caffeine toxicity, including tachycardia, feeding intolerance, jitteriness, and (at very high levels) seizures. Dose adjustment and serum caffeine level monitoring may be needed in infants with renal or hepatic impairment. Neocafen is intended strictly for use in the neonatal intensive care setting under specialist supervision, not for outpatient or general use. See Interactions for guidance on concurrent theophylline use.

Overdose of Neocafen can cause serious toxicity, including tachycardia, agitation, tremor, vomiting, and seizures, generally associated with serum caffeine levels exceeding 50 mg/L. Any suspected overdose of Neocafen requires immediate medical attention; management is supportive and directed by the treating medical team. Contact the treating physician, hospital emergency services, or a poison control center immediately if overdose is suspected.

Store Neocafen at room temperature, 20°C to 25°C (68°F to 77°F); protect from light. It is supplied as a preservative-free, single-use solution - discard any unused portion after opening. Keep out of reach of children and unauthorized personnel; administer only under hospital/NICU conditions.

Neocafen is indicated specifically for premature infants (approximately 28 to less than 33 weeks gestational age); safety and efficacy in full-term infants, older children, and adults have not been established, and it is not intended for these populations. In infants with hepatic or renal impairment, elimination of Neocafen is further prolonged, and serum caffeine level monitoring is recommended. There is no established adult or geriatric indication for Neocafen.

Duration of Neocafen therapy is individualized by the neonatology team, typically continuing until the infant reaches a postmenstrual age at which apnea of prematurity is expected to resolve (commonly around 34-37 weeks postmenstrual age), and clinical apnea episodes have resolved. Discontinuation timing is based on ongoing clinical assessment, not a fixed duration.

Caffeine Citrate is classified under: Methylxanthines; Central Nervous System Stimulants; Respiratory Stimulants (Neonatal).

Caffeine Citrate acts mainly as a non-selective adenosine receptor antagonist, blocking inhibitory adenosine signaling in the central nervous system. This increases central respiratory drive, improves diaphragmatic muscle contractility, enhances chemoreceptor sensitivity to carbon dioxide, and reduces the frequency and severity of apneic episodes in premature infants.

C

Neocafen is specifically approved for pediatric use only in premature infants (approximately 28 to less than 33 weeks gestational age) for treatment of apnea of prematurity, administered under neonatology specialist supervision with weight-based dosing. It is not approved for use in full-term neonates, infants, or older children. Because of immature hepatic metabolism, elimination half-life in preterm infants (approximately 3-4 days) is much longer than in older children or adults, requiring cautious dosing intervals and monitoring for toxicity.